But that isn't all Genentech had to offer cancer doctors at the ASCO conference.
Many of the other studies unveiled at the ASCO conference are backing up this contention.
We already know that a few winners are going to be presented at this year's ASCO.
Just because a cancer drug shows great results at ASCO doesn't guarantee its future.
The acquisitions were made through Asco's Canadian onshore oilfield services company, Moko, which is based in Alberta.
The Asco Group said it had acquired Alberta-based EJR Trucking, Manatokan Oilfield Logistics and Docktor Oilfield Transport Corporation.
At this year's meeting of the American Society for Clinical Oncology (ASCO), held earlier this week in Orlando, Fla.
That is why ASCO and the Journal of Clinical Oncology accept such data for publication, it is scientifically reliable.
FORBES: Why The New Dendreon Analysis Does Matter -- And Why It Doesn't
There will also be kidney cancer data related to SU11248 presented at ASCO.
Many of the cancer companies likely to present good data there could see significant run-ups ahead of the ASCO meeting.
Asco said the deals would significantly increase its capacity in Canada and support the group's international investment and growth plans.
As with Tarceva, Genentech issued a press release shortly before the 2003 ASCO meeting, saying that Avastin had extended patients' lives.
Flaherty says that cancer doctors cajoled the two sides to discuss a combo trial at the June ASCO meeting of cancer doctors.
But initial results being presented at a press briefing at ASCO did not reach statistical significance in preventing colon cancer from progressing.
The acquisitions double Asco's staff numbers in Canada to more than 260.
Today, Miller is presenting early data for the first time here at the annual meeting of the American Society for Clinical Oncology (ASCO).
The results of the study are being announced on Monday at a meeting of the American Society of Clinical Oncology (ASCO) in San Francisco.
This year's meeting of the American Society of Clinical Oncology (ASCO) is a "building year, " says David Parkinson, head of oncology at Biogen Idec.
But an advisory board convened by the ASCO told doctors to stick with tamoxifen and use Arimidex only when the older drug doesn't work.
The final safety data on the drug will be presented at ASCO, and Porges thinks they will determine whether doctors really use the drug.
That is not to say that the new drugs being presented at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, Fla.
Bernstein writes in a note to investors that the drug company has more presentations at ASCO this year than the rest of the biotech industry combined.
The latest deals, combined with the acquisition of North Sea Lifting in June, have boosted the number of Asco employees worldwide from 1, 600 to more than 2, 000.
The 29-year-old firm has dominated this year's biggest cancer treatment conference, the annual meeting of the American Society of Clinical Oncology (ASCO), with its drugs Herceptin, Avastin and Tarceva.
At ASCO, Anthony Tolcher of the Institute for Drug Development in San Antonio, presented results from an initial trial showing that it dramatically shrank tumors in five of 41 patients tested.
"All men considering testing for prostate cancer should be fully informed by their clinicians about their risk factors and other uncertainties before being screened, " a statement from ASCO President Dr. Douglas Blaney said.
CNN: Let men decide on prostate screening, cancer society says
The full data from both of those studies will be presented at ASCO, as will another study showing that the company's Herceptin prevents breast cancer tumors with certain genetic defects from returning after surgery.
Most striking is the complete absence of the traditional "ASCO effect, " the run-up in biotechnology stocks ahead of the annual meeting of the American Society for Clinical Oncology, which will be held in Chicago in early June.
应用推荐